Phase 1 — Early testing in a small group of people (usually 20–80) to evaluate safety, determine safe dosage, and identify side effects.
Trial locations(7 sites)
France
Hôpital Européen Georges Pompidou, Paris Centre Eugène Marquis, Rennes Gustave Roussy, Villejuif, France Italy
Humanitas Research Hospital, Milan Istituto Europeo di Oncologia, Milan Centro Ricerche Cliniche Verona, Verona